This study included 855 patients diagnosed with malignancy or metastatic lesion, both of which were severe cases of kidney cancer.
The scientists invited these patients to take part in an experiment that used a combination of the three drugs. The process took from 17.7 to 20 months.
Often doctors offer patients with cancer the so-called “first-line treatment” that includes immunotherapy, which is the use of drugs aimed at boosting the body’s immune system.
In this experiment, the researchers decided to go even further by adding a new inhibitor to the treatment, a molecule that can “block” the activity of certain proteins in cancer cells.
The results were impressive: Patients who received the new drug combination showed a significant improvement in progression-free survival compared to those who received standard immunotherapy alone.
Overall, the risk of developing or dying from cancer is reported to be 27% lower.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
